CVS Health announced the appointment of four new board members - Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman - following productive discussions with Glenview Capital Management on November 17, 2024. The board expansion increases its size from 12 to 16 members. Norwalk will join the Health Services Committee, Sansone the Audit Committee, and Shulman the Management Planning and Development Committee.The company also disclosed compensation changes for key executives. CEO David Joyner's package includes a $1.5M base salary, $3M target bonus, and $14.5M long-term incentive opportunity. EVP Prem Shah will receive a $1.1M base salary, $1.925M target bonus, and $9M long-term incentive. Additionally, both executives received premium-priced stock options, while Chief Digital Officer Tilak Mandadi was granted a $3M restricted stock unit retention award.As part of the agreement, Glenview Capital agreed to certain standstill provisions until the 2026 annual meeting nomination window. The partnership aims to enhance CVS Health's integrated business model and drive greater financial and operational performance through the new directors' industry expertise.

CVS Health announced the appointment of four new board members - Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman - following productive discussions with Glenview Capital Management on November 17, 2024. The board expansion increases its size from 12 to 16 members. Norwalk will join the Health Services Committee, Sansone the Audit Committee, and Shulman the Management Planning and Development Committee.The company also disclosed compensation changes for key executives. CEO David Joyner's package includes a $1.5M base salary, $3M target bonus, and $14.5M long-term incentive opportunity. EVP Prem Shah will receive a $1.1M base salary, $1.925M target bonus, and $9M long-term incentive. Additionally, both executives received premium-priced stock options, while Chief Digital Officer Tilak Mandadi was granted a $3M restricted stock unit retention award.As part of the agreement, Glenview Capital agreed to certain standstill provisions until the 2026 annual meeting nomination window. The partnership aims to enhance CVS Health's integrated business model and drive greater financial and operational performance through the new directors' industry expertise.